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Abstract
Potassium calcium-activated channel subfamily N member 2 (KCNN2) encodes an integral membrane protein that forms small-
conductance calcium-activated potassium (SK) channels. Recent studies in animal models show that SK channels are important in
atrial and ventricular repolarization and arrhythmogenesis. However, the importance of SK channels in human arrhythmia remains
unclear. The purpose of the present study was to test the association between genetic polymorphism of the SK2 channel and the
occurrence of cardiac tachyarrhythmias in humans. We enrolled 327 Han Chinese, including 72 with clinically signiﬁcant ventricular
tachyarrhythmias (VTa) who had a history of aborted sudden cardiac death (SCD) or unexplained syncope, 98 with a history of atrial
ﬁbrillation (AF), and 144 normal controls. We genotyped 12 representative tag single nucleotide polymorphisms (SNPs) across a 141-
kb genetic region containing the KCNN2 gene; these captured the full haplotype information. The rs13184658 and rs10076582
variants of KCNN2 were associated with VTa in both the additive and dominant models (odds ratio [OR] 2.89, 95% conﬁdence
interval [CI]=1.505–5.545, P=0.001; and OR 2.55, 95% CI=1.428–4.566, P=0.002, respectively). After adjustment for potential
risk factors, the association remained signiﬁcant. The population attributable risks of these 2 variants of VTa were 17.3% and 10.6%,
respectively. One variant (rs13184658) showed weak but signiﬁcant association with AF in a dominant model (OR 1.91, CI=
1.025–3.570], P=0.042). There was a signiﬁcant association between the KCNN2 variants and clinically signiﬁcant VTa. These
ﬁndings suggest an association between KCNN2 and VTa; it also appears that KCNN2 variants may be adjunctive markers for risk
stratiﬁcation in patients susceptible to SCD.
Abbreviations: AF = atrial ﬁbrillation, CI = conﬁdence interval, GWAS = genome-wide association studies, HWE =
Hardy–Weinberg equilibrium, ICD = implantable cardioverter-deﬁbrillator, KCNN2 = potassium calcium-activated channel subfamily
Nmember 2, KCNN3= potassium calcium-activated channel subfamily Nmember 3, LD= linkage disequilibrium, MAF=minor allele
frequencies, OR = odds ratio, PAR = population attributable risk, SCD = sudden cardiac death, SK = small-conductance calcium-
activated potassium, SK2 = small-conductance calcium-activated potassium channel subtype 2, SNP = single nucleotide
polymorphism, VF = ventricular ﬁbrillation, VT = ventricular tachycardia, VTa = ventricular tachyarrhythmias.
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The genetic basis of ventricular tachyarrhythmias (VTa) and
sudden cardiac death (SCD) remains unclear. Even when exposed
to the same risk factors, such as ischemic or nonischemic
cardiomyopathy, inherited channelopathies, or metabolic syn-
drome, some patients experience lethal arrhythmias while others
have minimal symptoms.[1–4] These ﬁndings suggest that
unknown disease modiﬁers play a role in the differential
outcomes among these patients.
Small-conductance calcium-activated potassium (SK) currents
are repolarization currents responsible for afterhyperpolarization
of the neurons in the central nervous system.[5,6] Recent studies
have demonstrated the existence of SK currents in the atrial
myocytes that are responsible for atrial repolarization.[7–9] The
SK current is downregulated in diabetic mouse atria and in
human chronic atrial ﬁbrillation (AF).[10,11] Inhibition of SK
current is proarrhythmic in healthy atria but antiarrhythmic in
atrial tachypacing-induced remodeled atria due to the associated
increase in action potential duration.[12–15] Although SK current
is either very small or undetectable in normal ventricular
myocytes paced at normal rates,[16–18] it is important for
ventricular repolarization in normal hearts with bradycardia
and/or hypokalemia, as well as in ischemic and failing
ventricles.[18–25] Upregulation of SK current in failing hearts is
responsible for postshock action potential duration shortening
and recurrent spontaneous ventricular ﬁbrillation (VF).[18]
Although blocking SK current in failing rabbit hearts may act
as an antiarrhythmic by suppressing electrical storm, it may also
reduce repolarization reserve and induce early afterdepolariza-
tion and torsades de pointes ventricular arrhythmia.[24] There-
fore, the role of SK current upregulation or downregulation in
ventricular arrhythmia is complex, depending on the clinical
scenario.[26,27] Nevertheless, these ﬁndings suggest that SK
channels may play an important role in the pathogenesis of
ventricular arrhythmia.
SK channels have 3 subtypes, encoded as potassium calcium-
activated channel subfamily N member 1, 2, and 3 (KCNN1,
KCNN2, and KCNN3). Among these, variants of KCNN3 are
known to be associated with AF,[28] and SK channel subtype 2
(SK2) is known to be upregulated in failing human hearts and
plays an important role in ventricular repolarization.[19,20]
Although genetic variants are known to be associated with
human cardiac arrhythmogenesis,[29,30] there are no reported
associations between genetic variants of theKCNN2 gene and the
risk of cardiac arrhythmias. The purpose of the present study was
to test the association betweenKCNN2 common genetic variants
and cardiac arrhythmias, including both VTa and AF.2. Methods
The study protocol was in accordance with the Declaration of
Helsinki and was approved by the Institutional Ethical
Committee of National Taiwan University Hospital. All study
subjects signed informed consent before participation.
2.1. Study populations
In a single tertiary referring medical center (National Taiwan
University Hospital), 2 groups of patients were consecutively and
prospectively enrolled. Group 1 was a deﬁned VTa population
that included the following: patients (N=69) who received
implantable cardioverter-deﬁbrillator (ICD) implantation for
secondary prevention, including survivors of cardiac arrest due to2VF or hemodynamically unstable sustained ventricular tachycar-
dia (VT) after evaluation to deﬁne the cause of the event and to
exclude any completely reversible cause; and patients (N=3) with
unexplained syncope with clinically relevant, hemodynamically
signiﬁcant sustained VT or VF induced at electrophysiological
study. Group 2 (N=98) included patients with drug-refractory
paroxysmal or persistent AF who underwent pulmonary vein
isolation by radiofrequency catheter ablation. The control
population (N=144) comprised patients admitted to the Health
Management Center of National Taiwan University Hospital.
The latter patients did not have diabetes, hypertension,
dyslipidemia, or coronary artery disease based on history,
physical examination, routine laboratory testing, electrocardio-
gram, and chest X-ray. Due to wide range of minor allele
frequencies (MAF) over different populations, only Han Chinese
were enrolled.2.2. Selection of SNPs and genotyping
Using the HapMap CHB databank (public data release 27 phase
II+ III, February 2009), 78 single nucleotide polymorphisms
(SNPs) were identiﬁed in a 141-kb region containing KCNN2, 5
kb upstream, and 1kb downstream using Haploview software
(version 4.2).[31] Twelve tag SNPs (rs6884289, rs7710366,
rs2416371, rs11738819, rs10076582, rs338625, rs13181189,
rs163305, rs12516818, rs1599175, rs13184658, and
rs12652782) were selected, capturing 100% of haplotype
variance for all SNPs on KCNN2 with a minimum r[2] value
of 0.8 and MAF≥5%. All SNP markers were genotyped by
matrix-assisted laser desorption/ionization-time of ﬂight mass
spectrometry at the National Center for Genome Medicine, and
the experimental protocol can be summarized as follows. A DNA
fragment (100–300bp) encompassing the SNP site was ampliﬁed
using a polymerase chain reaction GeneAmp 9700 thermal cycler
(Applied Biosystems, Foster City, CA) according to the
manufacturer’s instructions. After polymerase chain reaction,
ampliﬁcation, and neutralization of the deoxynucleotide triphos-
phates, primer extension was performed by adding the probe,
Thermo Sequenase (Amersham Pharmacia, Piscataway, NJ), and
an appropriate dideoxynucleotide triphosphate/deoxynucleotide
triphosphates mixture. Extension products were differentiated by
matrix-assisted laser desorption/ionization-time of ﬂight. We
then compared the reference allele frequency and MAF of our
population with other populations recorded in the HapMap
databank (Supplemental Table S1, http://links.lww.com/MD/
B136).2.3. Statistical analysis
Baseline characteristics of the groups were compared using
Student unpaired t test (continuous data) or chi-square test
(categorical data). For each SNP, the more common allele in the
controls was assigned as the reference category. A Hardy–-
Weinberg equilibrium (HWE) test was performed for each
sequence variant of the control group before marker-trait
association analysis. The association of each SNP allele with
VTa or AF and control was assessed using logistic regression in
models of codominant, dominant, and recessive inheritance. In
the model of genotyping analysis, age and sex were adjusted by
multivariant logistic regression. For further robust signiﬁcant
association, nominal 2-sided P values were corrected for multiple
tests by 10,000 permutations with Haploview software.[31] For
haplotype construction, genotype data from the case and control
Table 1
Clinical characteristics.
Controls (n=144) VTa (n=72) AF (n=98) Pa Pb
Age, years 56.2±13.9 58.9±15.0 57.3±10.6 0.178 0.504
Sex (male) 54.2% 79.2% 80.6% <0.001 <0.001
Smoking 22.5% 26.4% 16.1% 0.564 0.347
Drinking 15.9% 11.1% 22.6% 0.383 0.266
BMI 24.1±3.4 25.5±6.0 24.9±3.0 0.070 0.077
Diabetes – 20.8% 16.3% – –
HTN – 47.2% 38.8% – –
Hyperlipidemia – 31.9% 50.0% – –
CAD – 25.0% 11.2% – –
AF= atrial ﬁbrillation, BMI=body mass index, CAD= coronary artery disease, HTN=hypertension, Pa= comparison between control and patients with SCD, Pb=comparison between control and patients with
AF, SCD= sudden cardiac death, VTa= ventricular tachyarrhythmias.
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(LD) by measuring pairwise D0 and r2 and deﬁning LD blocks.
We used the conﬁdence interval (CI) method component of the
Haploview software to deﬁne an LD block with an extended
spine if D0 was >0.8.[32] The population attributable risk (PAR)
was estimated from the control group data as follows: p (OR
1)/[p (OR1)+1], in which p is the prevalence of risk allele
among control subjects and OR is the odds ratio of the risk
allele.[33] All statistical analyses were performed in IBM SPSS
Statistics V20. A 2-sided P0.05 was considered statistically
signiﬁcant.3. Results
3.1. Baseline characteristics
In total, there were 72 patients with history of VTa and 98
patients with AF. The underlying etiologies of the VTa were
dilated cardiomyopathy in 31 (43.1%), ischemic cardiomyopa-
thy in 20 (27.8%), and non-heart failure in 21 (29.1%), including
14 (19.4%) with idiopathicVF, 3 (4.2%) with Brugada
syndrome, 2 (2.8%) with arrhythmogenic right ventricular
cardiomyopathy, 1 (1.4%) with hypertrophic cardiomyopathy,
and 1 (1.4%) with long QT syndrome. All the other clinical
characteristics are listed in Table 1. VTa is the most disastrous
and common end-stage presentation of patients with various
cardiovascular diseases, especially those with congestive heart
failure of different etiologies. There may be a common factor that
predisposes these patients to VTa. Therefore, in the present study,
we enrolled a group with various underlying diseases to
investigate the association of KCNN2 SNPs with VTa.Figure 1. Graphical representation of single nucleotide polymorphisms in
relation to the exon-intron structure (upper line) and Haploview LD graph of the
KCNN2 gene (middle and lower panels). The exon regions are shown as ﬁlled
rectangles and are numbered in order. Pairwise LD coefﬁcients D0100 are
shown in each cell (D0 values of 1.0 are not shown). A standard Haploview color
schemewas applied to the LD color display (LOD score≥2 and D0=1 shown in
bright red; LOD score≥2 and D0<1 shown in pink; LOD score<2 and D0=1
shown in blue; LOD score<2 and D0<1 shown in white). The middle panel
shows the association with ventricular tachyarrhythmias; lower panel shows
the association with atrial ﬁbrillation. KCNN2=potassium calcium-activated
channel subfamily N member 2, LD= linkage disequilibrium, LOD= logarithm of
odds.3.2. Association between KCNN2 SNPs and VTa
There are up to 78 common SNPs in the humanKCNN2 gene. To
decrease genotyping effort, we only genotyped representative tag
SNPs. We selected tags that captured most of haplotype variance
for all SNPs on the KCNN2 gene. Ten tag SNPs, not including
rs13181189 and rs12516818, were successfully genotyped,
capturing 89% of haplotype variance. For these 10 SNPs, the
success rate of genotyping was 99.7% (range: 99.1%–100%). A
graphic representation of the SNPs in relation to the exon-intron
structure (according to the National Center for Biotechnology
Information) is shown in Fig. 1, middle panel. All the SNPswere in
the introns. The genomic position, nucleic acid composition,MAF,
HWEtestP values,OR, andnominal and permutedP-values of the3
Table 2
Allele association of the 10 tag SNPs in the KCNN2 gene with the risk of sudden cardiac death.
VTa AF
No. Name
Gene
position, kb
Gene
regions
Major/
minor allele control %
HW P
value
OR
(95% CI) Pa Pb %
HW
P value
OR
(95% CI) Pa Pb
1 rs163305 15.7 Intron 3–4 G/C 0.378 0.403 0.486 1.11 (0.738–1.675) 0.613 1.000 0.448 0.254 1.34 (0.922–1.939) 0.125 0.731
2 rs13184658 33.8 Intron 3–4 G/A 0.094 0.188 0.871 2.27 (1.275–4.040) 0.005 0.037 0.160 0.076 1.84 (1.059–3.192) 0.029 0.270
4 rs338625 66.2 Intron 4–5 C/T 0.135 0.201 0.515 1.61 (0.949–2.732) 0.078 0.515 0.186 0.079 1.46 (0.887–2.386) 0.124 0.729
5 rs2416371 79.2 Intron 4–5 C/T 0.101 0.174 0.183 1.88 (1.053–3.342) 0.033 0.249 0.120 0.083 1.22 (0.680–2.172) 0.510 1.000
6 rs10076582 81.2 Intron 4–5 T/C 0.185 0.326 0.701 2.13 (1.347–3.370) 0.001 0.009 0.258 0.708 1.53 (0.984–2.367) 0.089 0.633
7 rs7710366 83.5 Intron 4–5 G/T 0.146 0.160 1.0 1.11 (0.640–1.936) 0.704 1.000 0.133 0.528 0.90 (0.529–1.517) 0.715 1.000
8 rs12652782 94.6 Intron 4–5 C/T 0.080 0.069 0.049 0.87 (0.404–1.887) 0.730 1.000 0.093 0.036 1.18 (0.618–2.247) 0.618 1.000
9 rs1599175 95.0 Intron 4–5 C/T 0.052 0.118 0.572 2.52 (1.217–5.200) 0.013 0.086 0.078 0.761 1.54 (0.736–3.234) 0.248 0.948
11 rs6884289 111.1 Intron 5–6 A/G 0.322 0.368 0.387 1.23 (0.807–1.869) 0.337 0.964 0.375 0.394 1.27 (0.862–1.856) 0.292 0.977
12 rs11738819 123.8 Intron 6–7 G/T 0.149 0.167 0.763 1.16 (0.672–2.000) 0.596 1.000 0.141 0.811 0.93 (0.554–1.568) 0.792 1.000
AF= atrial ﬁbrillation, CI= conﬁdence interval, HW=Hardy–Weinberg equilibrium, KCNN2=potassium calcium-activated channel subfamily N member 2, OR= odds ratio, Pa=nominal P value, Pa=permuted P
value, SNP= single nucleotide polymorphism, VTa= ventricular tachyarrhythmias.
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from the expected count by HWE (rs12657682, P=0.049).
We ﬁrst compared the allele frequencies of all the SNPs of case
and control patients. Interestingly, 4 variants (rs13184658,
rs2416371, rs10076582, and rs1599175) showed signiﬁcant
association with VTa. Among these, 2 SNPs (the A variant of
rs13184658 and C variant of rs10076582) remained signiﬁcant
after 10,000 permutations (Table 2) and Bonferroni correction.
The OR of rs13184658 was 2.27 (95% CI=1.275–4.040;
permutated P=0.037; P=0.046 with Bonferroni correction) and
that of rs10076582 was 2.13 (95% CI=1.347–3.370, permuted
P=0.009; P=0.011 with Bonferroni correction). The estimated
PARs were 17.3% and 10.6%, respectively. There was no LD
detected.
Genotypic analysis (Table 3) showed signiﬁcant association of
4 SNPs (rs13184658, rs338625, rs10076582, and rs1599175)
with VTa. All except rs1599175 revealed signiﬁcant association
in a dominant model. There was no homozygous risk allele for
rs1599175. After adjustment for age and sex, all the associations
remained signiﬁcant. After further adjustment for other riskTable 3
Genotype association analysis.
No Name Case Control
2 rs13184658
GG 63.4 83.3
GA 35.2 14.6
AA 1.4 2.1
GA+AA
4 rs338625
CC 61.1 77.1
CT 37.5 18.8
TT 1.4 4.2
CT+TT
6 rs10076582
TT 44.0 67.1
TC 45.8 28.7
CC 9.7 4.2
TC+CC
9 rs1599175
CC 75.7 89.6
CT 24.3 10.4
CI= conﬁdence interval, OR= odds ratio, Pa=nominal P value, Pb= adjusted for age and sex, Pc= adjus
4factors, including smoking, drinking, and body mass index,
rs13184658, rs338625, and rs10076582 still showed signiﬁcant
association with VTa.
Further analysis was attempted to elucidate the SNP effect
among subgroups relative to underlying disease by grouping
them as dilated cardiomyopathy, ischemic cardiomyopathy, and
non-heart failure (Table 4). However, the power of the analysis
was limited due to the relatively small number of cases.
Nonetheless, similar trends of positive association were still
observed among all three subgroups, implicating the KCNN2
genetic variant as a common factor predisposing patients to VTa.3.3. Association between SNPs and AF
Based on the standardized pairwise LD coefﬁcient D0 and
estimated r2 of the markers, 2 LD blocks were identiﬁed across
the gene (Fig. 1, lower panel). One SNP (A allele of rs13184658)
showed signiﬁcant association with AF (OR 1.84, 95% CI=
1.059–3.192, P=0.029). This SNP was located in LD block 1 in
intron 3. The haplotypes within this LD block were signiﬁcantlyOR (95% CI) Pa Pb Pc
1.00 (ref)
3.18 (1.618–6.227) 0.001 0.001 0.010
0.89 (0.090–8.769) 0.920 0.796 0.432
2.89 (1.505–5.545) 0.001 0.001 0.010
1.00 (ref)
2.52 (1.333–4.773) 0.004 0.005 0.044
0.42 (0.049–3.594) 0.429 0.417 0.535
2.14 (1.160–3.950) 0.015 0.017 0.044
1.00 (ref)
2.42 (1.314–4.437) 0.005 0.008 0.114
3.50 (1.096–11.182) 0.035 0.034 0.031
2.55 (1.428–4.566) 0.002 0.003 0.044
1.00 (ref)
2.76 (1.284–5.924) 0.009 0.021 0.083
ted for age, sex, body mass index, hypertension, diabetes, dyslipidemia, and coronary artery disease.
Table 4
Subgroup analysis.
No. Name
Control
(N=144)
DCM
(n=31)
Ischemic
CM (n=20)
Non-HF
(n=21)
DCM
(n=31)
Ischemic
CM (n=20)
Non-HF
(n=21)
2 rs13184658
GG 83.3 70.0 65.0 52.4 1.00 (ref) 1.00 (ref) 1.00 (ref)
GA 14.6 26.7 35.0 47.6 2.17 (0.853–5.556) 3.08 (1.099–8.612) 5.20 (1.962–13.756)
AA 2.1 3.3 0.0 0.0 1.91 (0.189–19.193) – –
GA+AA 2.14 (0.875–5.247) 2.69 (0.973–7.451) 4.55 (1.737–11.895)
4 rs338625
CC 77.1 67.7 60.0 52.4 1.00 (ref) 1.00 (ref) 1.00 (ref)
CT 18.8 29.0 40.0 47.6 1.76 (0.726–4.277) 2.74 (1.202–7.365) 3.74 (1.440–9.703)
TT 4.2 3.2 0.0 0.0 0.88 (0.101–7.698) - -
CT+TT 1.60 (0.686–3.738) 2.24 (0.846–5.947) 3.06 (1.194–7.831)
6 rs10076582
TT 67.1 48.4 45.0 38.1 1.00 (ref) 1.00 (ref) 1.00 (ref)
TC 28.7 38.7 45.0 57.1 1.87 (0.807–4.350) 2.34 (0.867–6.325) 2.00 (0.214–18.721)
CC 4.2 12.9 10.0 4.8 4.27 (1.076–16.912) 3.56 (0.624–20.258) 3.51 (1.336–9.232)
TC+CC 2.18 (0.993–4.782) 2.50 (0.968–6.439) 3.32 (1.287–8.559)
9 rs1599175
CC 89.6 79.3 80.0 66.7 1.00 (ref) 1.00 (ref) 1.00 (ref)
CT 10.4 20.7 20.0 33.3 2.24 (0.789–6.383) 2.15 (0.635–7.276) 4.30 (1.500–12.326)
CM= cardiomyopathy, DCM=diastolic cardiomyopathy, non-HF=non-heart failure.
Yu et al. Medicine (2016) 95:29 www.md-journal.comassociated with AF. Among these haplotypes, the haplotype C-A
was associated with an increased risk of AF (P=0.02). However,
both associations became insigniﬁcant after 10,000 permutations
and Bonferroni correction. In a genotyping test, this variant,
rs13184658, showed signiﬁcant association in a dominant model
(OR 1.91, 95% CI=1.025–3.570, P=0.042). After adjustment
for age and sex, the associations remained signiﬁcant (OR 3.20,
95% CI=1.020–3.809, P=0.044).4. Discussion
We found a signiﬁcant association between common KCNN2
variants and sustained VTa in a group of consecutively enrolled
patients undergoing ICD implantation for secondary prevention
of SCD. Two SNPs (rs13184658 and rs10076582) showed
signiﬁcant association with VTa in a dominant model, carrying
2.55- to 2.89-fold increased risk. The association was robust, as it
remained signiﬁcant after adjustment for multiple potential risk
factors. These results suggested that SK2 current may play a role
in the mechanism of human VTa.4.1. Previous genetic association studies with the
intermediate phenotype of SCD
Earlier genome-wide association studies (GWAS) and candidate
gene analyses identiﬁed many rare or common variants that are
associated with intermediate phenotypes predictive of SCD risk,
including quantitative ECG traits, risk of coronary artery disease,
and autonomic function.[34–37] However, the effects of variants
associated with intermediate phenotypes were not consistent in
later studies,[38] suggesting heterogeneity of underlying genetic
causes for those phenotypes.[39] Although conducting a GWAS
study to identify SCD genes directly might be a more
comprehensive and attractive approach, not all risk variants
can be detected by this approach due to its limited power,
particularly in the regions that are not well covered by this
technique. Focusing on speciﬁc candidate genes based on
accumulated knowledge from in vivo and in vitro studies and
directly using the targeted phenotype, as we have done in this5study, is an efﬁcient method of identifying potentially important
risk allele(s).4.2. Second hit theory: KCNN2 variants predispose
patients to a greater risk of SCD
Previous studies also showed that while certain rare or common
variants (AT1R, ADRB2, SCN5A, KCNH2, and NOS1AP)
might not be directly associated with signiﬁcant clinical
arrhythmia syndromes, they affected carriers and predisposed
them to malignant arrhythmia when exposed to a 2nd hit, like
heart failure or myocardial ischemia.[40–43] Similar scenarios
could also be seen in cases of acquired long QT syndrome and
ischemic cardiomyopathy, in which rare variants (KCNH2,
KCNE1, KCNE2, KCNQ2, SCN5A, and RyR2 in drug-induced
long QT syndrome and CASQ2, RAB3GAP1, ZNF365,
CXADR, GPC5, GPD1L, NOS1AP, and SCN5A in ischemic
cardiomyopathy) were associated with higher risk of malignant
arrhythmia and SCD.[44–49] In Brugada syndrome, the variants at
SCN5A–SCN10A have a strong impact on susceptibility to
SCD.[50] Population-based studies have also found associations
between SCD and variants in AGTR1, AGTR2, NOS1AP,
SCN5A, and ADRB2.[51–54] In the present study, although the
underlying disease etiologies were diverse, a shared trait linked
patients to VTa. The association ofKCNN2 variants with VTa in
patients with a heterogeneous background implied a role of
KCNN2 in susceptibility to SCD when exposed to a 2nd hit (an
environmental or nongenetic factor) regardless of the underlying
cardiac pathology. This was also supported by the ﬁnding of our
subgroup analysis that all 3 groups have similar trends of positive
association.4.3. Trend of association of KCNN2 genetic
polymorphisms with AF
We also found a weak association between KCNN2
(rs13184658) and AF. An earlier GWAS study of lone AF
patients showed an association with variants ofKCNN3, another
subtype of the SK family, but not with KCNN2.[28,55–57]
Yu et al. Medicine (2016) 95:29 MedicineHowever, downregulation of both SK2 and SK3 currents was
observed in human chronic AF,[8] and ablation of SK2 channels
resulted in a delay in cardiac repolarization and atrial
arrhythmias.[7] Overexpression of the SK3 channels in transgenic
mice led to bradyarrhythmias and heart block but not to
ventricular arrhythmias.[58] Our ﬁnding of an association
between AF and KCNN2 further conﬁrms that SK currents
are important in the generation or maintenance of AF.4.4. Potential mechanisms of the association between
KCNN2 variants and SCD
The pathophysiological roles of the associated KCNN2 polymor-
phisms remain unknown. All the polymorphisms are in intron
regions and are not directly transcribed to the structure of the SK2
protein. Recent studies have shown that noncoding microRNAs
(miRs), which are mainly produced in the intergenic or intron
regions, play an important regulating role in gene expression, and
may possibly be involved in the pathophysiology of numerous
cardiovascular diseases. A single miR can regulate multiple genes,
and a single gene can be regulated by multiple miRs.[59–61] It is
possible that some of the polymorphisms in the LD block that is
associated with our tag SNPs (rs13184658 and rs10076582) are
true disease-associated SNPs and are involved in themechanism of
SCD at the epigenetic level mediated by miRs, affecting either
KCNN2 or other related genes’ activities. Because SK currentsmay
serve as rescue currents that maintain repolarization reserve in
disease conditions,[26] alteration of SK current activity may
contribute to cardiac arrhythmogenesis. However, further studies
are needed to conﬁrm or dismiss this possibility.4.5. Limitations
There are several limitations to this study. First, we used the tag
SNP association approach to search for common variants
associated with common phenotypes among sporadic cases.
This approach depends on LD to identify associated SNPs.
Therefore, the true responsible variants may not be identiﬁed.
Direct sequencing for all exons and introns to identify possible
rare variants might be another approach, but this would
dramatically increase the study cost without increasing the
statistical power signiﬁcantly. Family aggregation analysis would
be another approach.However, we did not pursue detailed family
histories or acquire blood samples from other family members.
Most of the patients were sporadic cases, and we made sure that
only 1 patient in each family was indexed in this study. Without
knowing the exact responsible variant, further in-depth func-
tional study was not possible. Second, the number of cases in this
study is relatively small. Expanding the case numbers for this
study or repeating the study results in another independent group
of patients is another attractive option. Because it is not easy to
clarify the association between SK2 and ventricular arrhythmias,
we decided to recruit only patients with the most extreme
phenotypes (lethal ventricular arrhythmias) who received ICD
implantation for secondary prevention. Expanding the patient
group to hemodynamically stable VTs or other intermediate
phenotypes might increase the probability of false negative
results. Third, the frequency of the variants in a population can
affect the PAR and may vary signiﬁcantly among different
populations (Supplemental Table S1, http://links.lww.com/MD/
B136). It appears that most KCNN2 gene variants have much
lower frequency in Han Chinese than in Caucasians. It is possible
that the KCNN2 variants reported in this cohort are not6associated with arrhythmias in other populations. Validation of
our ﬁndings in other populations, particularly among the
Caucasians, is warranted. Last, while we attempted to capture
100% of the haplotype variance using 12 tagging SNPs, we failed
to genotype 2 of these. Therefore, we only analyzed 10 SNPs,
capturing 89% of the haplotype variance. Among the 10
variants, 1 (rs12652782) deviated from HWE. This may be due
to the low frequency of the minor allele (as shown in Table 2 and
the Supplemental Table S1, http://links.lww.com/MD/B136), a
small sampling size, or both.5. Conclusion
Variants of the KCNN2 gene are associated with the occurrence
of lethal ventricular arrhythmias in patients with underlying
heart diseases. The clinical impact of these results remains unclear
and deserves further study.
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